Indoco Remedies · NSE: INDOCO · BSE: 532612
Q2 FY25 results · Jul–Sep 2024
Indoco Remedies reported revenue from operations of ₹432.66 crore (down 10.2% from Q2 FY24) and net loss of ₹10.01 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 432.66 | 481.73 | −10.2% | 431.49 | +0.3% |
| Other income | 1.56 | 4.43 | −64.8% | 1.03 | +51.5% |
| Total income | 434.22 | 486.16 | −10.7% | 432.52 | +0.4% |
| Profit before tax | (4.84) | 46.28 | Turned loss | 6.97 | Turned loss |
| Net profit for the period | (10.01) | 35.24 | Turned loss | 1.82 | Turned loss |
| Attributable to shareholders of the company | (9.57) | 35.08 | Turned loss | 2.62 | Turned loss |
| EPS, basic (₹) | (1.09) | 3.82 | Turned loss | 0.20 | Turned loss |
| Net margin (%) | -2.3 | 7.3 | 0.4 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 396.53 | 473.39 | −16.2% | 401.43 | −1.2% |
| Other income | 4.20 | 1.12 | +275.0% | 3.52 | +19.3% |
| Total income | 400.73 | 474.51 | −15.5% | 404.95 | −1.0% |
| Profit before tax | 17.38 | 44.03 | −60.5% | 19.51 | −10.9% |
| Net profit for the period | 12.79 | 33.14 | −61.4% | 14.95 | −14.4% |
| EPS, basic (₹) | 1.39 | 3.60 | −61.4% | 1.62 | −14.2% |
| Net margin (%) | 3.2 | 7.0 | 3.7 |
Consolidated
- Filed with BSE
- 06 Nov 2024, 10:37 IST
- Board meeting
- 24 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2024, 10:37 IST
- Board meeting
- 24 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE